Back

Safety concerns following the use of ketamine as a potential antidepressant for adolescent rats of both sexes

Jornet-Plaza, J.; Ledesma-Corvi, S.; Garcia-Fuster, M. J.

2024-11-11 pharmacology and toxicology
10.1101/2024.11.08.622617 bioRxiv
Show abstract

While ketamine is already approved for treatment resistant depression in adult patients, its efficacy and safety profile for its use in adolescence still needs further investigations. Preclinical studies proved dose- and sex-dependent effects induced by ketamine during adolescence, but few studies have evaluated the short- and long-term safety profile of ketamine at the doses necessary to induce its antidepressant-like effects. The present study aimed at evaluating the antidepressant-like effects of ketamine (1, 5 or 10 mg/kg; vs. vehicle; 1 vs. 7 days) during adolescence in naive or early-life stressed (i.e., maternal deprivation) rats of both sexes in the forced-swim or novelty-suppressed feeding tests. Safety was evaluated by measuring the psychomotor- and reinforcing-like responses induced by adolescent ketamine. In addition, long-term safety was evaluated in adulthood at the level of cognitive performance, or addiction liability (induced by a challenge dose of ketamine in rats treated with adolescent ketamine). The main results reinforced the potential for ketamine as an antidepressant for adolescence, but at different dose ranges for each sex. However, some safety concerns emerged for adolescent female rats (i.e., signs of sensitization at the dose used as antidepressant) and adult male rats (i.e., addiction liability when re-exposed to ketamine in adulthood), suggesting the need for caution and further research before moving forward the use of ketamine as an antidepressant for adolescence.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Journal of Psychopharmacology
14 papers in training set
Top 0.1%
12.3%
2
Psychopharmacology
59 papers in training set
Top 0.1%
8.2%
3
Neuropsychopharmacology
134 papers in training set
Top 0.3%
8.2%
4
PLOS ONE
4510 papers in training set
Top 29%
6.2%
5
Neuropharmacology
60 papers in training set
Top 0.1%
6.2%
6
Frontiers in Psychiatry
83 papers in training set
Top 0.8%
4.2%
7
Frontiers in Pharmacology
100 papers in training set
Top 0.7%
3.9%
8
ACS Pharmacology & Translational Science
40 papers in training set
Top 0.1%
3.9%
50% of probability mass above
9
British Journal of Pharmacology
34 papers in training set
Top 0.1%
3.9%
10
Pharmacology Biochemistry and Behavior
17 papers in training set
Top 0.1%
3.5%
11
International Journal of Neuropsychopharmacology
11 papers in training set
Top 0.1%
3.5%
12
Drug and Alcohol Dependence
37 papers in training set
Top 0.3%
2.8%
13
Translational Psychiatry
219 papers in training set
Top 2%
2.7%
14
Journal of Psychiatric Research
28 papers in training set
Top 0.2%
2.7%
15
Scientific Reports
3102 papers in training set
Top 52%
2.0%
16
The Journal of Pharmacology and Experimental Therapeutics
15 papers in training set
Top 0.1%
1.8%
17
Pharmaceuticals
33 papers in training set
Top 0.7%
1.7%
18
Biomedicines
66 papers in training set
Top 1%
1.6%
19
Life Sciences
25 papers in training set
Top 0.7%
1.5%
20
Journal of Clinical Medicine
91 papers in training set
Top 4%
1.3%
21
International Journal of Molecular Sciences
453 papers in training set
Top 13%
0.9%
22
Neurotherapeutics
11 papers in training set
Top 0.4%
0.9%
23
European Neuropsychopharmacology
15 papers in training set
Top 0.6%
0.7%
24
Biochemical Pharmacology
18 papers in training set
Top 0.2%
0.7%
25
Frontiers in Public Health
140 papers in training set
Top 8%
0.7%
26
Progress in Neuro-Psychopharmacology and Biological Psychiatry
36 papers in training set
Top 1%
0.7%
27
Journal of Affective Disorders
81 papers in training set
Top 2%
0.7%
28
ACS Chemical Neuroscience
60 papers in training set
Top 3%
0.6%
29
Behavioural Brain Research
70 papers in training set
Top 1%
0.6%
30
Epidemiology and Psychiatric Sciences
10 papers in training set
Top 0.5%
0.6%